LIfT BioSciences is a global leader in neutrophil immunotherapies for rejuvenating immune competence. The platform is initially being focused on overcoming treatment resistance in cancer but will also be deployed in longevity, auto-immune, anti-microbial resistance and dementia.
Led by Dr. Tony De Fougerolles – Founding CSO of Moderna, CSO Ablynx, VP Research Alnylam; centrally involved in bringing 2 Nobel prize winning discoveries to market. LIfT® is closing a £22.5m 2nd close + with £10m done in 1st close and having just secured a further £11m in grant money. The funding takes LIft through Phase I trials with interims in early 2027. LIfT also has early iPSC CAR-IMAN & tri-specific innate and adaptive immune engager pharma collaborations.
